Index to Volume 6, 1987
(No. 1 pp 1–66; No. 2 pp 67–116; No. 3 pp 117–174; No 4 pp 175–233)

Adjuvant chemotherapy
  causing
    hallucinations, 160
    psychotropic effects, 160–161
Adrenergic-neurone-blockers
  and phaeochromocytoma, 102
  causing
    depression, 153
    psychotropic effects, 153
β-Adrenoceptor blockers — *see* Beta-blockers
Adrenolytic procedures and phaeochromocytoma, 93–94
Adverse reactions
  assessment methods, 4–32
    BARDI, 21, 30, 32
    comparisons, 23–29
    pharmaceutical industry's, 16–21, 31–32
    regulatory authorities', 13–16, 31
  diagnosis, 2–32
Affective reactions, 142–143
Aflatoxicosis, 175, 176, 184–185, 186
  epidemiology, 188–191
  histology, 184
Aflatoxin
  activation, 182
  and infectious disease, 192–197
    kwashiorkor, 197–199
    Reye's syndrome, 186–187, 219
  biosynthesis, 176–177
  body fluid content, 183–184
  breast milk content, 180
  causing
    cancer, 188–192
    cirrhosis, 187–188
    embryotoxicity, 199
    hepatitis, 187, 188
    hepatoma, 189–192
    hepatomegaly, 187
    teratogenicity, 199
  chemical structure, 177–178
  excretion, 183
  food contamination with, 179
  history, 175–176
  ingestion, 179–181
  mechanisms of toxicity, 199–201
  metabolism, 181–182
Alcuronium, anaesthetic reactions, 130, 132
Althesin, anaesthetic reactions, 131
Amphotericin B, psychotropic effects, 160
Anaesthesia
  and phaeochromocytoma, 95–96
  causing
    anaphylaxis 118–122, 124
    direct histamine release, 125–126
    psychotropic effects, 150
Anaesthetic reactions,
  and atopic subjects, 123, 124, 134
    basophil release, 127–128
    complement activation, 129
    drug-specific antibodies, 136
    Ig E detection, 118–120, 124, 128, 135
    Ig G antibodies, 128–129, 133
    leucocyte histamine release, 135, 136
    mast cells, 120, 124–125
    skin, 122
  assessment, 133–136
  caused by
    alcuronium, 130, 132
    althesin, 131
    cremophor EL, 131
    dextrans, 131, 133
    gallamine, 130–131, 132
    methohexitone, 129, 132
    muscle relaxants, 129–131
    pancuronium, 132
    suxamethonium, 129–130, 132
    thiopentone, 129, 132
    tubocurarine, 130, 132
  causing
    anaphylaxis, 118–122, 124
    bronchospasm, 122–123
    convulsions, 123
    gastrointestinal symptoms, 123
    shock, 123
  clinical features, 122–123
  epidemiology, 117–118
  investigation, 134–136
  mechanisms, 126–129
  passive cutaneous anaphylaxis in, 127, 135
  predisposing factors, 123–124
  skin tests in, 126–127, 135–136
Analgesics
  causing
    hallucinations, 149
    paranoid psychosis, 149
    psychotropic effects, 149–150
Anaphylactoid reactions, 119, 121
Anaphylaxis, 118–122, 124
  and anaesthesia, 118–122, 124
    coagulation, 120
    histamine, 120, 124–125
    IgE, 118–120, 124
    IgG antibodies, 128–129
    kinin system, 120
    mast cells, 120
    proteases, 120

passive cutaneous, 127, 135
pathogenesis, 119–121
Antiarrhythmic drugs, psychotropic effects, 153–154
Antiasthmatic medications, psychotropic effects, 149
Antibodies, drug specific, 136
Anticonvulsants
cognitive effects, 154
psychotropic effects, 154
Antifungal drugs, psychotropic effects, 160
Antihistamines
and phaeochromocytoma, 96
psychotropic effects, 158–159
Antihypertensives, psychotropic effects, 151–153
Antimalarials, psychotropic effects, 160
Antimony
absorption, 71–72
adverse effects, acute, 72
treatment, 82–83
carcinogenicity, 76, 81
cardiovascular effects, 79–80
chemistry, 69–70
dermatological effects, 78–79
detection, 70
distribution, 72–73
excretion, 73
exposure to, 70
fetal effects, 81
haematological effects, 80
hepatic effects, 79
metabolic effects, 79
musculoskeletal effects, 80–81
mutagenicity, 76, 81
pharmacokinetics, 71–74
pharmacological action, 73–74
renal effects, 79
reproductive effects, 75, 81
respiratory effects, 78
teratogenicity, 75–76
toxic effects, 74–83
epidemiology, 83, 84
treatment, 82–83
toxicology, 74–83
animal, 74–76
human, 76–83
uses, 67–69, 71
current, 71
historical, 67–69
industrial, 71
medical, 71
visual effects, 81
Antiparkinsonian drugs, psychotropic effects, 154–155
Antituberculous agents, psychotropic effects, 159
Anxiety
caused by
caffeine, 148
cimetidine, 158
CNS stimulants, 147, 148, 149
corticosteroids, 156
oral contraceptives, 156
Appetite suppressants, psychotropic effects, 148–149
Aspirin and Reye's syndrome, 218–219, 220
Atopy and anaesthetic reactions, 123, 124, 134
Atropine and phaeochromocytoma, 96

Baclofen
causing
hallucinations, 155
manic psychosis, 155
psychotropic effects, 155
Basophils and anaesthetic reactions, 127–128
Behavioural toxicity, 142–143
Benzodioxane and phaeochromocytoma, 93–94, 104–105
Beta-blockers
and phaeochromocytoma, 96, 102
causing
depression, 152, 153
hallucinations, 152
nightmares, 152
psychotropic effects, 151–153
vivid dreams, 152
Bethanidine, psychotropic effects, 153
Book reviews, 111–116, 169–174
Bromocriptine, psychotropic effects, 155
Bronchospasm in anaesthetic reactions, 122–123

Caffeine
causing
anxiety, 148
psychotropic effects, 148
Carbamazepine, psychotropic effects, 154
Carcinogenesis
aflatoxin, 188–192
epidemiology, 188–191
antimony, 76, 81
Cardiovascular drugs, psychotropic effects, 150–154
Cardiovascular shock, anaesthetic reactions, 123
Chloroquine
causing
behavioural toxicity, 160
delirium, 160
depression, 160
psychotropic effects, 160
Chlorotrianisene, pharmacology, 39–40
Chlorpromazine and phaeochromocytoma, 96

Cimetidine
causing
anxiety, 158
delirium, 158
depression, 158
hallucinations, 158
mania, 159
paranoia, 158
psychotropic effects, 158–159
therapy, alcohol consumption and, 158
Cirrhosis caused by aflatoxin, 187–188
Clomiphene citrate, psychotropic effects, 158
Clonidine
and phaeochromocytoma, 100
causing
delirium, 151
depression, 151
hallucinations, 151
paranoia, 151
psychotropic effects, 151
CNS stimulants
causing
anxiety, 147–148, 149
hallucinations, 147, 148, 149
paranoid psychoses, 147, 148, 149
psychotropic effects, 147–149
Coagulation and anaphylaxis, 120
Cognitive function and anticonvulsants, 154
Complement activation in anaesthetic reactions, 129
Convulsions in anaesthetic reactions, 123
Corticosteroids
and phaeochromocytoma, 102
causing
anxiety, 156
depression, 155, 156
hypomania, 156
psychotropic effects, 155–156
Corticotrophin and phaeochromocytoma, 95, 99, 102
Cremophor EL causing anaesthetic reactions, 131
Curare and phaeochromocytoma, 96
Cyclopropane and phaeochromocytoma, 96

Debrisoquine, psychotropic effects, 153
Decongestants, psychotropic effects, 148
Delirium, 142–143
caused by
chloroquine, 160
cimetidine, 158
clonidine, 151
digoxin, 153
Dementia, 142–143
Depression
caused by
adrenergic-neurone-blockers, 153
beta-blockers, 152, 153
chloroquine, 160
cimetidine, 158
clonidine, 151
corticosteroids, 155–156
digoxin, 153
diuretics, 153
methyldopa, 151
nadolol, 153
NSAIDs, 150
oral contraceptives, 156, 157
oxprenolol, 153
propranolol, 152
Dextrans and anaesthetic reactions, 131, 133
Diagnostic tests for phaeochromocytoma, 91–95
Digoxin
causing
delirium, 153
depression, 153
hallucinations, 153
psychotropic effects, 153
Diuretics
causing
depression, 153
hallucinations, 153
psychotropic effects, 153
Droperidol and phaeochromocytoma, 96, 103

Embryotoxicity and aflatoxin, 199
Ether and phaeochromocytoma, 96
Ethinyloestradiol, metabolism, 41

Fertility drugs, psychotropic effects, 158

Gallamine
and phaeochromocytoma, 96
causing anaesthetic reactions, 130–131, 132
Gastrointestinal effects of anaesthetic reactions, 123
Glucagon and phaeochromocytoma, 92–93, 99
Guanethidine
and phaeochromocytoma, 102
psychotropic effects, 153

Hallucinations, 142, 143, 147, 148, 149, 151, 152, 153, 154, 155, 159, 160, 161
caused by
adjuvant chemotherapy, 160
analgesics, 149
baclofen, 155
beta-blockers, 152
cimetidine, 158
clonidine, 151
CNS stimulants, 147, 148, 149
digoxin, 153
diuretics, 153
propranolol, 153
radiological contrast media, 159, 160

reserpine, 151
Halothane and phaeochromocytoma, 96
Hepatitis caused by aflatoxin, 187–188
Hepatoma caused by aflatoxin, 189–192
Hepatomegaly caused by aflatoxin, 187
Histamine
and phaeochromocytoma, 91–92, 98, 100
direct release by anaesthetics, 125–126
in anaphylaxis, 120, 124–125
leucocyte release of, 135, 136
Hypertensive crises caused by phaeochromocytoma, 97–104
Hypomania caused by corticosteroids, 156
Hypotensive reactions caused by phaeochromocytoma, 104

IgE
detection of, 128, 135, 136
in anaesthetic reactions, 118–120, 124
anaphylaxis, 118–120, 124
IgG antibodies
in anaesthetic reactions, 128–129, 133
anaphylaxis, 128–129
Imipramine and phaeochromocytoma, 95, 101
Infectious disease and aflatoxin, 192–197
Insecticides in Reye's syndrome, 219–220
Insulin and phaeochromocytoma, 93, 99, 101

Kinin system in anaphylaxis, 120
Kwashiorkor and aflatoxin, 197–199

Labetalol and phaeochromocytoma, 96
Leucocyte histamine release in anaesthetic reactions, 135, 136

Manic psychosis
caused by
baclofen, 155
cimetidine, 159
muscle relaxants, 155
Manic symptoms, 142, 155, 159
Mast cells
in acute drug reactions, 124–125
anaesthetic reactions, 120, 124–125
anaphylaxis, 120
Mestranol, metabolism, 41
Methacholine and phaeochromocytoma, 92, 98
Methohexitone causing anaesthetic reactions, 129, 132
Methoxyflurane and phaeochromocytoma, 96
Methyldopa
causing
depression, 151
nightmares, 151
psychotropic effects, 151
vivid dreams, 151
Methylphenidate causing psychotropic effects, 147–148
Metoclopramide
and phaeochromocytoma, 95, 103
psychotropic effects, 159
Metrizamide, psychotropic effects, 159–160
Mood changes
caused by
oral contraceptives, 157
sex hormones, 157–158
Muscle relaxants
causing
anaesthetic reactions, 129–131, 132
manic psychosis, 155
psychotropic effects, 155
Mutagenicity caused by antimony, 76, 81

Nadolol causing depression, 153
Neuropsychiatric states, 142–144
Nicotine and phaeochromocytoma, 101
Nightmares
caused by
beta-blockers, 152
methyldopa, 151
propanolol, 152
NSAIDs
causing
depression, 150
paranoid psychosis, 150
psychotropic effects, 150

Oestrogens, 37–59
absorption, 40
biotransformation, 41
causing
breast cancer, 51–52
cardiovascular disease, 53–54
cerebrovascular disease, 55
cervical cancer, 50
cholelithiasis, 55
depression, 45–46
endometrial carcinoma, 51, 52
genitourinary abnormalities, 51
growth inhibition, 44
impaired glucose tolerance, 55
liver tumours, 52–53
neoplasia, 50–53
psychiatric illness, 54
renal cancer, 53
vaginal cancer, 50
chemistry, 38–39
distribution, 40–41
efficacy of, 46–50
excretion, 41–42
implants, 57
metabolism, 40–41
pharmacology, 38–40

structures, 38–39
topical, 56–57
toxicity, 50–55
uses
abortion prevention, 44
acne, 45
alopecia, 45
aphthous ulcers, 45
breast cancer therapy, 49–50
dysfunctional uterine bleeding, 44
dysmenorrhoea, 44
growth inhibition, 44
haemostasis, 46
hirsutism, 45
hyperlipidaemia, 45
lactation, 46–47
menopause, 47–49
non-medical, 43
osteoporosis, 48–49
prostatic cancer, 49–50
provocation test, 44
replacement therapy, 47–49
Turner's syndrome, 44, 47
Opiates and phaeochromocytoma, 96
Oral contraceptives
causing
anxiety, 156
depression, 156, 157
mood changes, 157
psychotropic effects, 156–158
Oxprenolol
causing
depression, 153
psychotropic effects, 153

Pancuronium causing anaesthetic reactions, 131
Paranoid psychoses, 142–143, 147, 148, 149, 150, 151, 153, 158, 160, 161
caused by
cimetidine, 158
clonidine, 151
CNS stimulants, 147, 148, 149
NSAIDs, 150
scopolamine, 161
tocainide, 153
Pentolinium and phaeochromocytoma, 100
Phaeochromocytoma
and adrenergic-neurone-blockers, 102
adrenolytic procedures, 93–94
anaesthetics, 95, 96
antihistamines, 96
atropine, 96
benzodioxane, 93–94, 104–105
beta-blockers, 96, 102
chlorpromazine, 96
clonidine, 100
corticosteroids, 102
corticotrophin, 95, 99, 102
curare, 96
cyclopropane, 96
droperidol, 96, 103
ether, 96
gallamine, 96
glucagon, 92–93, 99
guanethidine, 102
halothane, 96
histamine, 91–92, 98, 100
hypertensive crises, 97–104
hypotensive reactions, 104
imipramine, 95, 101
insulin, 93, 99, 101
labetalol, 96
methacholine, 92, 98
methoxyflurane, 96
metoclopramide, 95, 103
nicotine, 101
opiates, 96
pentolinium, 100
phenoxybenzamine, 103
phentolamine, 94, 104–105
plasma expanders, 96
prednisolone, 102
saralasin, 95, 103–104
steroids, 96
sulpiride, 103
suxamethonium, 96
tetraethylammonium, 92, 98–99
thiopentone, 96
tobacco, 95
trichlorethylene, 96
tricyclic antidepressants, 101
trimetaphan, 96
tubocurarine, 96
tyramine, 92, 99, 100–101
diagnostic tests, 91–95
provocative tests, 91–93
suppression tests, 95
Phenoxybenzamine and phaeochromocytoma, 103
Phentolamine and phaeochromocytoma, 94, 104–105
Phenytoin, psychotropic effects, 154
Plasma expanders and phaeochromocytoma, 96
Podophyllin, psychotropic effects, 161
Prednisolone and phaeochromocytoma, 102
Propranolol
causing
depression, 152
hallucinations, 152
nightmares, 152
psychotropic effects, 151–153
vivid dreams, 152
Proteases and anaphylaxis, 120
Provocative tests in phaeochromocytoma, 91–93

Psychotropic adverse reactions, 141–161
caused by
adjuvant chemotherapy, 160–161
adrenergic-neurone-blockers, 153
amphotericin B, 160
anaesthetics, 150
analgesics, 149–150
antiarrhythmic drugs, 153–154
antiasthmatic medications, 149
anticonvulsants, 154
antifungal drugs, 160
antihistamines, 158–159
antihypertensives, 151–153
antimalarials, 160
antiparkinsonian drugs, 154–155
antituberculous agents, 159
appetite suppressants, 148–149
baclofen, 155
beta-blockers, 151–153
bethanidine, 153
bromocriptine, 155
caffeine, 148
carbamazepine, 154
cardiovascular drugs, 150–154
chloroquine, 160
cimetidine, 158–159
clomiphene citrate, 158
clonidine, 151
CNS stimulants, 147–149
corticosteroids 155–156
debrisoquine, 153
decongestants, 148
digoxin, 153
diuretics, 153
fertility drugs, 158
guanethidine, 153
methyldopa, 151
methylphenidate, 147–148
metoclopramide, 159
metrizamide, 159–160
muscle relaxants, 155
NSAIDs, 150
oral contraceptives, 156–158
oxprenolol, 153
paranoid psychosis, 142–143, 147, 148, 149, 150, 151, 153, 158, 160, 161
phenytoin, 154
podophyllin, 161
propranolol, 151–153
radiological contrast media, 159–160
scopolamine, 161
sex hormones, 157–158
sodium valproate, 154
tocainide, 153
identification, 144–146
mechanisms, 144
reporting, 147
types, 142–144
affective, 142–143
behavioural toxicity, 142–143
delirium, 142–143
dementia, 142–143
depression, 142
hallucinations, 142, 143, 147, 148, 149, 151, 152, 153, 154, 155, 159, 160, 161
neuropsychiatric, 142–144
schizophreniform, 142–143

Radiological contrast media
causing
hallucinations, 159–160
psychotropic effects, 159–160
Reserpine, causing hallucinations, 151
Reye's syndrome, 185–187, 211–228
aetiology, 216–221
agents suspected
aflatoxin, 186–187, 219
aspirin, 218–219, 220
drugs, 218–221
insecticides, 219–220
toxins, 218–221
biochemical features, 213–215
clinical features, 212–213
differential diagnosis, 214
encephalopathy in, 224
genetic factors, 221–222
intracranial pressure, 226–227
management, 225–228
metabolic factors in pathogenesis, 222–223
morbidity, 213
mortality, 213
pathology, 215–216
cerebral lesions, 216
hepatic lesions, 215–216
skeletal muscle lesions, 216
treatment, 224–228

Saralasin and phaeochromocytoma, 95, 103–104
Schizophrenia-like states, 142–143
Scopolamine
causing
paranoia, 161
psychotropic effects, 161
Sex hormones
causing
mood changes, 157–158
psychotropic effects, 157–158
Skin
in anaesthetic reactions, 122
tests in anaesthetic reactions, 126–127, 135–136
Sodium valproate, psychotropic effects, 154
Steroids and phaeochromocytoma, 96

Stilboestrol
as breast cancer therapy, 49–50
causing
breast cancer, 51–52
cardiovascular disease, 53
cervical carcinoma, 50
endometrial carcinoma, 51, 52
genitourinary abnormalities, 51
hirsutism, 45
liver tumours, 53
neoplasia, 50–53
psychiatric illness, 54
renal carcinoma, 53
toxicity, 49
vaginal carcinoma, 50
in treatment of breast cancer, 49–50
prostatic cancer, 49–50
obstetric uses, 37
pharmacology, 39
provocation test, 44
Sulpiride and phaeochromocytoma, 103
Suppression tests in phaeochromocytoma, 95
Suxamethonium
and phaeochromocytoma, 96
causing anaesthetic reactions, 129–130, 132

Tamoxifen in breast cancer, 50
Teratogenicity of aflatoxin, 199
antimony, 75–76
Tetraethylammonium and phaeochromocytoma, 92, 98–99
Thiopentone
and phaeochromocytoma, 96
causing anaesthetic reactions, 129–132
Tobacco and phaeochromocytoma, 95
Tocainide
causing
paranoid psychosis, 153
psychotropic effects, 153
Trichlorethylene and phaeochromocytoma, 96
Tricyclic antidepressants and phaeochromocytoma, 101
Trimetaphan and phaeochromocytoma, 96
Tubocurarine
and phaeochromocytoma, 96
causing anaesthetic reactions, 130, 132
Tyramine and phaeochromocytoma, 92, 99, 100–101